How This $4.3 Billion Pharma Company Is Helping Underserved Patients in Neuro
Richard Pops, Chairman & CEO of AlkermesAlkermes For over 30 years, Richard Pops has been the CEO of Alkermes (NASDAQ: ALKS), a company steadfastly focused on neuroscience—a notoriously challenging therapeutic area with highly stigmatized patient …